InNexus Biotechnology, Inc.
IXSBF · OTC
6/30/2010 | 6/30/2009 | 6/30/2008 | 6/30/2007 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -93.4% | – |
| Cost of Goods Sold | $0 | $0 | $1 | $0 |
| Gross Profit | $0 | $0 | -$1 | -$0 |
| % Margin | – | – | -60,403.4% | -1,583.8% |
| R&D Expenses | $1 | $2 | $4 | $2 |
| G&A Expenses | $2 | $4 | $0 | $0 |
| SG&A Expenses | $2 | $4 | $5 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$3 | -$3 | -$1 |
| Operating Expenses | $4 | $7 | $6 | $5 |
| Operating Income | -$4 | -$7 | -$6 | -$5 |
| % Margin | – | – | -565,567.3% | -33,603.6% |
| Other Income/Exp. Net | $4 | -$1 | -$0 | -$0 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$8 | -$6 | -$5 |
| % Margin | – | – | -582,934.9% | -33,861.5% |
| EPS | -0.07 | -0.11 | -0.11 | -0.13 |
| % Growth | 36.4% | 0% | 15.4% | – |
| EPS Diluted | -0.07 | -0.11 | -0.11 | -0.13 |
| Weighted Avg Shares Out | 96 | 75 | 55 | 44 |
| Weighted Avg Shares Out Dil | 96 | 75 | 55 | 44 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3 | $1 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $1 | $0 |
| EBITDA | -$3 | -$6 | -$5 | -$5 |
| % Margin | – | – | -515,888.8% | -35,991.8% |